Cargando…

In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that leads to coronavirus disease (COVID-19) has put public health at risk in 2020. The spike protein (SP) in SARS-CoV-2 is primarily responsible for the attachment and entry of the virus into the cell, which binds to the angiotensin-conve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buitrón-González, Ivonne, Aguilera-Durán, Giovanny, Romo-Mancillas, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834266/ https://www.ncbi.nlm.nih.gov/pubmed/33520633 http://dx.doi.org/10.1016/j.rechem.2020.100094

Ejemplares similares

Computational Study of C-X-C Chemokine Receptor (CXCR)3 Binding with Its Natural Agonists Chemokine (C-X-C Motif) Ligand (CXCL)9, 10 and 11 and with Synthetic Antagonists: Insights of Receptor Activation towards Drug Design for Vitiligo
por: Aguilera-Durán, Giovanny, et al.
Publicado: (2020)

Behavior of Chemokine Receptor 6 (CXCR6) in Complex with CXCL16 Soluble form Chemokine by Molecular Dynamic Simulations: General Protein‒Ligand Interaction Model and 3D-QSAR Studies of Synthetic Antagonists
por: Aguilera-Durán, Giovanny, et al.
Publicado: (2021)

Study of Endogen Substrates, Drug Substrates and Inhibitors Binding Conformations on MRP4 and Its Variants by Molecular Docking and Molecular Dynamics
por: Becerra, Edgardo, et al.
Publicado: (2021)

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
por: Nadler, Jeffrey P, et al.
Publicado: (2003)

Drug Repurposing Against Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Through Computational Approach
por: Vaseghi, Golnaz, et al.
Publicado: (2022)

Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir
por: Yu, Yuqi, et al.
Publicado: (2015)

Pharmacokinetics and drug-drug interaction between enalapril, enalaprilat and felodipine extended release (ER) in healthy subjects
por: Li, Dai, et al.
Publicado: (2017)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages
por: Borrajo, Ana, et al.
Publicado: (2017)

Identification of Structural Features for the Inhibition of OAT3-Mediated Uptake of Enalaprilat by Selected Drugs and Flavonoids
por: Ni, Yao, et al.
Publicado: (2020)

The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin
por: Dahlgren, David, et al.
Publicado: (2020)

Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats
por: Dahlgren, David, et al.
Publicado: (2021)

Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins
por: Halder, Umesh C.
Publicado: (2021)

Completing the Enalaprilat Excretion Pathway—Renal Handling by the Proximal Tubule
por: Smeets, Nori J. L., et al.
Publicado: (2020)

A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2)
por: Coghi, Paolo, et al.
Publicado: (2021)

Amprenavir inhibits pepsin‐mediated laryngeal epithelial disruption and E‐cadherin cleavage in vitro
por: Samuels, Tina L., et al.
Publicado: (2023)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J)
por: Kalamatianos, Konstantinos G.
Publicado: (2022)

Intravenous enalaprilat for treatment of acute hypertensive heart failure in the emergency department
por: Ayaz, Syed Imran, et al.
Publicado: (2016)

Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients—A Systematic Review
por: Faisal, Muhammad, et al.
Publicado: (2021)

Cardiac arrest and COVID-19: inflammation, angiotensin-converting enzyme 2, and the destabilization of non-significant coronary artery disease—a case report
por: Colombier, Sébastien, et al.
Publicado: (2020)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Revealing Origin of Decrease in Potency of Darunavir and Amprenavir against HIV-2 relative to HIV-1 Protease by Molecular Dynamics Simulations
por: Chen, Jianzhong, et al.
Publicado: (2014)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir.
por: Bawdon, R E
Publicado: (1998)

Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model
por: Choi, Yoonjung, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Effects of enalaprilat sodium on plasma NTproANP and NTproBNP levels in healthy volunteers
por: Heringlake, M, et al.
Publicado: (2006)

Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors
por: Bots, Sophie H., et al.
Publicado: (2022)

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
por: De Clercq, Erik
Publicado: (2019)

Angiotensin-converting enzyme 2 and new insights into the renin–angiotensin system
por: Lambert, Daniel W., et al.
Publicado: (2008)

Angiotensin-Converting Enzyme 2: The First Decade
por: Clarke, Nicola E., et al.
Publicado: (2012)

Angiotensin-converting enzyme 2 in lung diseases
por: Kuba, Keiji, et al.
Publicado: (2006)

Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan
por: Huang, Shiou-Huei, et al.
Publicado: (2012)

Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy
por: Tu, Bin, et al.
Publicado: (2021)

The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes
por: Blaine-Sauer, Simon, et al.
Publicado: (2023)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure
por: Patel, Vaibhav B., et al.
Publicado: (2012)

LC–MS/MS assay for quantitation of enalapril and enalaprilat in plasma for bioequivalence study in Indian subjects
por: Halder, Dhiman, et al.
Publicado: (2017)

Editorial: Drug Repurposing
por: Pantziarka, Pan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l10610b82ec680d48lc8qn6k9h